Procedure

6 cycles arm (n = 29)

>6 cycles arm (n = 30)

Surgery

Biopsy

6 (20.7%)

5 (16.7%)

Partial resection

9 (31.0%)

12 (40.0%)

Total gross resection

14 (48.3%)

(43.3%)

Treatment events

-Surgery only

3 (10.3%)

3 (10%)

-Surgery CCRT

26 (89.6%)

27 (90%)

-Radiotherapy to PTV (mean)

59.0 Gy ± (SD 2.58)

58.97 Gy ± (SD 2.23)

-Completed CCRT

21 (72.4%)

22 (73.3%)

(Cause of un completion)

-Toxicity

1 (3.8%)

2 (7.4%)

-Clinical deterioration

4 (15.3%)

3 (11.1%)

-Adjuvant TMZ

<6 cycles adjuvant TMZ

5 (17.2%)

3 (13.6%)

6 cycles adjuvant TMZ

16 (76.1%)

>6 cycles adjuvant TMZ

19 (86.3%)

Median No. of cycles

11

(Range)

(8 - 23 cycle)

Completed CCRT & adjuvant

N = 16 (55.1%)

N = 19 (63.3%)

Median PFS (month)

12.1

18.8 (P 0.01)

Median OS (month)

18.1

24.1 (P 0.04)

Median time to progression from last TMZ dose (month)

4.1 (1.3 - 16.5)

6.8 (1.8 - 20)

Treatment post progression

Surgery

4 (25.0%)

5 (26.3%)

TMZ 4 weekly

5 (31.3%)

3 (31.6%)

TMZ alternative schedule

3 (18.8%)

2 (10.5%)

Bevacizumab

3 (18.8%)

4 (21.0%)

All patients

N = 29

N = 30

Median PFS (month)

10.4

13.2 (P 0.038)

Median OS (month)

14.1

18.8 (P 0.07)

Treatment post progression

Surgery

4 (13.7%)

5 (16.6%)

TMZ 4 weekly

6 (20.7%)

8 (26.7%)

TMZ alternative schedule

3 (10.3%)

3 (10.0%)

Bevacizumab

4 (13.7 %)

4 (13.3%)

G3/4 toxicity

On CCRT

N = 26

N = 27

Thrombocytopenia

1 (3.8%)

2 (7.4%)

Neutropenia

1 (3.8%)

0

On adjuvant TMZ

N = 21

N = 22

Thrombocytopenia

1 (4.7%)

2 (9.0%)

Neutropenia

2 (7.6%)

4 (18%)

Anemia

0

1 (4.5%)